Alpha4 integrins as therapeutic targets in autoimmune disease.
von Andrian
Ulrich H
UH
Engelhardt
Britta
B
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D039441:Integrin alpha4 / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D009088:Mucoproteins / Q000378:metabolism; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D007136:Immunoglobulins; C504265:MADCAM1 protein, human; D009088:Mucoproteins; D000069442:Natalizumab; D039441:Integrin alpha4